Mineralys Therapeutics, Inc.
MLYS
$14.89
$0.2751.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -43.27M | -42.21M | -48.95M | -56.34M | -41.01M |
| Total Depreciation and Amortization | 16.00K | 15.00K | 15.00K | 11.00K | 9.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.32M | 2.60M | 1.80M | 427.00K | 25.00K |
| Change in Net Operating Assets | 10.77M | -5.89M | -19.71M | 5.72M | 10.83M |
| Cash from Operations | -30.17M | -45.49M | -66.84M | -50.19M | -30.15M |
| Capital Expenditure | -- | -- | 0.00 | -37.00K | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -42.88M | -92.88M | 83.57M | 79.64M | 7.74M |
| Cash from Investing | -42.88M | -92.88M | 83.57M | 79.61M | 7.74M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9.88M | 189.29M | 137.00K | 40.00K | 132.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -47.00K | -10.00K | -47.00K | -41.00K | -284.00K |
| Cash from Financing | 9.83M | 189.28M | 90.00K | -1.00K | -152.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -63.22M | 50.92M | 16.82M | 29.42M | -22.56M |